The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review
Abstract
Objective To define the clinical characteristics, management, and outcome of neurologic immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods Systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results A total of 694 articles were identified. Two hundred fifty-six articles, with 428 individual patients, met the inclusion criteria. Reports regarding neuromuscular disorders (319/428, 75%) were more frequent than those on CNS disorders (109/428, 25%). The most common n-irAEs reports were myositis (136/428, 32%), Guillain-Barré syndrome and other peripheral neuropathies (94/428, 22%), myasthenic syndromes (58/428, 14%), encephalitis (56/428, 13%), cranial neuropathies (31/428, 7%), meningitis (13/428, 3%), CNS demyelinating diseases (8/428, 2%), and myelitis (7/428, 2%). Other CNS disorders were detected in 25/428 (6%) patients. Compared with the whole sample, myasthenic syndromes were significantly more Ab positive (33/56, 59%; p < 0.001). Anti–programmed cell death protein 1/programmed cell death ligand 1 was more frequent in myasthenic syndromes (50/58, 86%; p = 0.005) and less common in meningitis (2/13, 15%; p < 0.001) and cranial neuropathies (13/31, 42%; p = 0.005). Anti–cytotoxic T-lymphocyte antigen-4 ICIs were more frequent in meningitis (8/13, 62%; p < 0.001) and less common in encephalitis (2/56, 4%; p = 0.009) and myositis (12/136, 9%; p = 0.01). Combination of different ICIs was more frequent in cranial neuropathies (12/31, 39%; p = 0.005). Melanoma was more frequent in patients with peripheral neuropathies (64/94, 68%; p = 0.003) and less common in encephalitis (19/56, 34%; p = 0.001). The highest mortality rate was reached in myasthenic syndromes (28%). Conclusion Considering the increasing use of ICI therapy in the forthcoming future, this information can be valuable in assisting neurologists and oncologists in early n-irAEs diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
The PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
Kao, J. C., Liao, B., Markovic, S. N., Klein, C. J., Naddaf, E., Staff, N. P., Liewluck, T., Hammack, J. E., Sandroni, P., Finnes, H., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1912 · Cited by 315
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 267
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Dubey, D., David, W. S., Reynolds, K. L., Chute, D. F., Clement, N. F., Cohen, J. V., Lawrence, D. P., Mooradian, M. J., Sullivan, R. J., & Guidon, A. C. (2020) · Annals of Neurology · doi:10.1002/ana.25708 · Cited by 244
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Kimura, T., Fukushima, S., Miyashita, A., Aoi, J., Jinnin, M., Kosaka, T., Ando, Y., Matsukawa, M., Inoue, H., Kiyotani, K., et al. (2016) · Cancer Science · doi:10.1111/cas.12961 · Cited by 192
Cited by
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Metadata
- Authors
- Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A.
- Venue
- Neurology
- Published
- 2021-04-20
- Volume
- 96
- Issue
- 16
- Pages
- 754-766
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3134562413
- Cited by
- 273
- References
- 40
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. https://app.cochat.ai/papers/10.1212/wnl.0000000000011795
- The paper
- Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A. (2021). Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. https://doi.org/10.1212/wnl.0000000000011795
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.